글루카곤 시장 : 제품 유형별, 용도별, 유통 채널별 - 기회 분석 및 산업 예측(2024-2033년)

Glucagon Market By Product Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,333,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,608,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

글루카곤 시장은 2023년에 3억 달러로 평가되었고, 2024년부터 2033년까지 6.4%의 연평균 복합 성장률(CAGR)로 2033년에는 6억 달러에 달할 것으로 예상됩니다.

글루카곤은 췌장의 α세포에서 생성되는 펩타이드 호르몬입니다. 혈당이 너무 낮아졌을 때 혈당을 상승시켜 체내 에너지 균형을 유지함으로써 포도당 대사에 중요한 역할을 합니다. 이 호르몬은 주로 간에서 작용하여 글리코겐의 분해(글리코겐 분해)를 촉진하고 비탄수화물 공급원으로부터의 포도당 생산(당생성)을 자극합니다. 글루카곤은 혈당을 낮추는 인슐린에 대항하여 작용합니다.

당뇨병, 특히 제 1형 당뇨병의 전 세계 유병률 증가는 심각한 저혈당을 관리하기 위한 중요한 치료법이기 때문에 글루카곤에 대한 수요를 주도하고 있습니다. 국제당뇨병연맹(2023년)은 전 세계적으로 5억 4,000만 명 이상의 성인이 당뇨병을 앓고 있는 것으로 추정하고 있으며, 이는 글루카곤 치료의 중요성을 강조하고 있습니다. 또한, 저혈당 관리에 대한 의료기관의 교육적 노력으로 인해 특히 심각한 저혈당 발생 위험이 높은 당뇨병 환자들 사이에서 글루카곤 제제 채택이 증가하고 있습니다. 또한, 노인 인구의 급격한 증가는 세계 시장의 주요 동력이 되고 있습니다. 전 세계 인구의 고령화로 인해 당뇨병 및 관련 합병증에 걸릴 위험이 높아지면서 글루카곤 제품에 대한 수요가 증가하고 있습니다. 세계보건기구(WHO)가 발표한 2024년 조사에 따르면, 2020년 10억 명의 노인 인구가 2030년까지 14억 명으로 증가할 것으로 예상하고 있습니다. 또한, 80세 이상 고령자 수는 2050년까지 4억 2,600만 명에 달할 것으로 추정됩니다. 또한, 글루카곤은 저혈당증에 대한 사용뿐만 아니라 소화관 이완을 위한 영상진단(방사선 검사, 내시경 검사 등)에의 채택도 증가하고 있어 그 시장 범위가 넓어지고 있습니다. 그러나 글루카곤 요법, 특히 비강 내 글루카곤과 같은 새로운 제제는 고가이기 때문에 특히 저소득 지역이나 의료보험이 충분하지 않은 환자에게는 접근성에 큰 장벽이 될 수 있습니다. 특히 응급상황에서 글루카곤을 사용하려면 일반적으로 적절한 투여를 위해 의료 전문가의 지도가 필요하며, 의료 지원을 즉시 받을 수 없는 상황에서는 사용이 더욱 제한적일 수 있습니다. 한편, 프리필드 주사기, 자동 주사기, 비강 내 글루카곤 제제 등의 기술 혁신으로 투약이 용이해져 환자와 간병인이 글루카곤 요법을 보다 쉽게 접하고 사용할 수 있게 되었습니다. 이러한 개발은 예측 기간 동안 세계 시장 확대의 새로운 길을 열어줄 것으로 예상됩니다.

세계 글루카곤 산업은 유형, 용도, 유통 채널 및 지역으로 분류됩니다. 유형별로 시장은 주사용 글루카곤과 비강용 글루카곤으로 분류됩니다. 용도별로는 저혈당증과 진단 보조제로 분류됩니다. 유통 채널에 따라 병원 약국, 소매 약국, 온라인 약국으로 세분화됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 주사제용 글루카곤이 2024년부터 2033년까지 시장을 장악할 것으로 예상됩니다.

용도별로는 저혈당증 분야가 예측 기간 동안 세계 시장 성장을 견인할 것으로 예상됩니다.

유통 채널별로는 병원 약국 부문이 예측 기간 동안 눈에 띄는 속도로 성장할 것으로 예상됩니다.

지역별로 보면, 글루카곤 시장은 북미에서 강력한 성장세를 보일 것으로 예상됩니다.

본 보고서의 커스터마이징이 가능합니다.(추가 비용과 일정이 있습니다.)

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 기업 프로파일 확장 목록
• 상환 시나리오

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 글루카곤 시장 : 제품 유형별

• 시장 개요
• 주사 글루카곤
• 경비 글루카곤

제5장 글루카곤 시장 : 용도별

• 시장 개요
• 저혈당
• 진단 보조

제6장 글루카곤 시장 : 유통경로별

• 시장 개요
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 글루카곤 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국 글루카곤 시장
  • 캐나다 글루카곤 시장
  • 멕시코 글루카곤 시장
• 유럽
  • 주요 시장 동향과 기회
  • 프랑스 글루카곤 시장
  • 독일 글루카곤 시장
  • 이탈리아 글루카곤 시장
  • 스페인 글루카곤 시장
  • 영국 글루카곤 시장
  • 기타 유럽 글루카곤 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국 글루카곤 시장
  • 일본 글루카곤 시장
  • 인도 글루카곤 시장
  • 한국 글루카곤 시장
  • 호주 글루카곤 시장
  • 기타 아시아태평양 글루카곤 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질 글루카곤 시장
  • 남아프리카공화국 글루카곤 시장
  • 사우디아라비아 글루카곤 시장
  • 기타 라틴아메리카, 중동 및 아프리카 글루카곤 시장

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2023년

제9장 기업 개요

• Novo Nordisk A/S
• Fresenius SE And Co. KGaA
• Amphastar Pharmaceuticals, Inc.
• Xeris Biopharma Holdings, Inc.
• ILS Inc
• United Biotech(P) Limited
• Zealand Pharma A/S
• Taj Pharmaceuticals Limited
• Eli Lilly And Company.
• Pfizer Inc.

LSH

영문 목차

영문목차

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Reimbursement Scenario

Key Market Segments

By Product Type

• Injectable Glucagon
• Nasal Glucagon

By Application

• Hypoglycemia
• Diagnostic Aid

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Novo Nordisk A/S
• Fresenius SE & Co. KGaA
• Amphastar Pharmaceuticals, Inc.
• Xeris Biopharma Holdings, Inc.
• ILS Inc
• United Biotech (P) Limited
• Zealand Pharma A/S
• Taj Pharmaceuticals Limited
• Eli Lilly and Company.
• Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Product Type
• 4.2. Injectable Glucagon
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Nasal Glucagon
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON MARKET, BY APPLICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Application
• 5.2. Hypoglycemia
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Diagnostic Aid
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Distribution Channel
• 6.2. Hospital Pharmacies
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Retail Pharmacies
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Online Pharmacies
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Product Type
  • 7.2.3. Market Size and Forecast, By Application
  • 7.2.4. Market Size and Forecast, By Distribution Channel
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Glucagon Market
    • 7.2.6.1. Market Size and Forecast, By Product Type
    • 7.2.6.2. Market Size and Forecast, By Application
    • 7.2.6.3. Market Size and Forecast, By Distribution Channel
  • 7.2.7. Canada Glucagon Market
    • 7.2.7.1. Market Size and Forecast, By Product Type
    • 7.2.7.2. Market Size and Forecast, By Application
    • 7.2.7.3. Market Size and Forecast, By Distribution Channel
  • 7.2.8. Mexico Glucagon Market
    • 7.2.8.1. Market Size and Forecast, By Product Type
    • 7.2.8.2. Market Size and Forecast, By Application
    • 7.2.8.3. Market Size and Forecast, By Distribution Channel
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Product Type
  • 7.3.3. Market Size and Forecast, By Application
  • 7.3.4. Market Size and Forecast, By Distribution Channel
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. France Glucagon Market
    • 7.3.6.1. Market Size and Forecast, By Product Type
    • 7.3.6.2. Market Size and Forecast, By Application
    • 7.3.6.3. Market Size and Forecast, By Distribution Channel
  • 7.3.7. Germany Glucagon Market
    • 7.3.7.1. Market Size and Forecast, By Product Type
    • 7.3.7.2. Market Size and Forecast, By Application
    • 7.3.7.3. Market Size and Forecast, By Distribution Channel
  • 7.3.8. Italy Glucagon Market
    • 7.3.8.1. Market Size and Forecast, By Product Type
    • 7.3.8.2. Market Size and Forecast, By Application
    • 7.3.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3.9. Spain Glucagon Market
    • 7.3.9.1. Market Size and Forecast, By Product Type
    • 7.3.9.2. Market Size and Forecast, By Application
    • 7.3.9.3. Market Size and Forecast, By Distribution Channel
  • 7.3.10. UK Glucagon Market
    • 7.3.10.1. Market Size and Forecast, By Product Type
    • 7.3.10.2. Market Size and Forecast, By Application
    • 7.3.10.3. Market Size and Forecast, By Distribution Channel
  • 7.3.11. Rest Of Europe Glucagon Market
    • 7.3.11.1. Market Size and Forecast, By Product Type
    • 7.3.11.2. Market Size and Forecast, By Application
    • 7.3.11.3. Market Size and Forecast, By Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Product Type
  • 7.4.3. Market Size and Forecast, By Application
  • 7.4.4. Market Size and Forecast, By Distribution Channel
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. China Glucagon Market
    • 7.4.6.1. Market Size and Forecast, By Product Type
    • 7.4.6.2. Market Size and Forecast, By Application
    • 7.4.6.3. Market Size and Forecast, By Distribution Channel
  • 7.4.7. Japan Glucagon Market
    • 7.4.7.1. Market Size and Forecast, By Product Type
    • 7.4.7.2. Market Size and Forecast, By Application
    • 7.4.7.3. Market Size and Forecast, By Distribution Channel
  • 7.4.8. India Glucagon Market
    • 7.4.8.1. Market Size and Forecast, By Product Type
    • 7.4.8.2. Market Size and Forecast, By Application
    • 7.4.8.3. Market Size and Forecast, By Distribution Channel
  • 7.4.9. South Korea Glucagon Market
    • 7.4.9.1. Market Size and Forecast, By Product Type
    • 7.4.9.2. Market Size and Forecast, By Application
    • 7.4.9.3. Market Size and Forecast, By Distribution Channel
  • 7.4.10. Australia Glucagon Market
    • 7.4.10.1. Market Size and Forecast, By Product Type
    • 7.4.10.2. Market Size and Forecast, By Application
    • 7.4.10.3. Market Size and Forecast, By Distribution Channel
  • 7.4.11. Rest of Asia-Pacific Glucagon Market
    • 7.4.11.1. Market Size and Forecast, By Product Type
    • 7.4.11.2. Market Size and Forecast, By Application
    • 7.4.11.3. Market Size and Forecast, By Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Product Type
  • 7.5.3. Market Size and Forecast, By Application
  • 7.5.4. Market Size and Forecast, By Distribution Channel
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Glucagon Market
    • 7.5.6.1. Market Size and Forecast, By Product Type
    • 7.5.6.2. Market Size and Forecast, By Application
    • 7.5.6.3. Market Size and Forecast, By Distribution Channel
  • 7.5.7. South Africa Glucagon Market
    • 7.5.7.1. Market Size and Forecast, By Product Type
    • 7.5.7.2. Market Size and Forecast, By Application
    • 7.5.7.3. Market Size and Forecast, By Distribution Channel
  • 7.5.8. Saudi Arabia Glucagon Market
    • 7.5.8.1. Market Size and Forecast, By Product Type
    • 7.5.8.2. Market Size and Forecast, By Application
    • 7.5.8.3. Market Size and Forecast, By Distribution Channel
  • 7.5.9. Rest of LAMEA Glucagon Market
    • 7.5.9.1. Market Size and Forecast, By Product Type
    • 7.5.9.2. Market Size and Forecast, By Application
    • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping Of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Novo Nordisk A/S
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Fresenius SE And Co. KGaA
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Amphastar Pharmaceuticals, Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Xeris Biopharma Holdings, Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. ILS Inc
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. United Biotech (P) Limited
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Zealand Pharma A/S
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Taj Pharmaceuticals Limited
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Eli Lilly And Company.
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments

관련자료